Please provide your email address to receive an email when new articles are posted on . Steven Yeh, MD, of Truhlsen Eye Institute, University of Nebraska Medical Center, said by 4 weeks, patients with ...
To evaluate the effect of four versus three loading aflibercept injections on macular fluid resolution and visual acuity (VA) in exudative neovascular AMD (nAMD). Multicentre, retrospective cohort ...
Age-related macular degeneration (AMD) is the primary cause of elderly blindness in industrialized countries 1. With the development of anti-vascular endothelial growth factor (VEGF) medication, the ...
Repeat treatment with corticosteroid injections improved vision in people with persistent or recurrent uveitis-related macular edema better than two other therapies, according to results from a ...
Injection medications can save the vision of older people with macular degeneration, but the ongoing regimen is taxing. Now a preliminary study raises the possibility that some patients can safely be ...
CHICAGO — The number of injections required for the successful treatment of neovascular age-related macular degeneration could be reduced considerably with experimental therapies, new research shows.
An injection that helps to block the growth of abnormal blood vessels in the back of the eye in patients with wet age-related macular degeneration (AMD) is set to become available on the NHS in ...
Regeneron Pharmaceuticals Inc REGN announced the first presentation of two-year (96 weeks) results from the pivotal PHOTON trial of aflibercept 8 mg with 12- and 16-week dosing regimens, compared to ...
Real-world diabetic macular edema care lags trials as fewer VEGF injections and step therapy limit outcomes. Persistent ...
Approval based on the pivotal PULSAR and PHOTON trials in which EYLEA® HD demonstrated clinically equivalent vision gains to EYLEA (aflibercept) Injection 2 mg that were maintained with fewer ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results